Microdrop delivery enhances adherence and comfort in glaucoma therapy

A microdrop delivery system using the Nanodropper adaptor outperformed conventional eyedrop dosing in reducing intraocular pressure (IOP) and minimizing medication waste among patients with glaucoma or ocular hypertension, according to results from a prospective, randomized crossover study.

The single-center trial enrolled adults on stable monotherapy with either latanoprost or timolol. Participants used conventional drops for 12 weeks and microdrops for 12 weeks, with masked examiners measuring outcomes.

Microdrops reduced IOP by an average of 1.6 mm Hg from baseline, compared with a 0.13-mm Hg reduction with standard drops. Premature bottle exhaustion dropped from 83% with conventional dosing to 17% with microdrops. Adverse events, including local irritation, were also less frequent with the microdrop approach (62% vs 83%).

Most participants reported that the microdrop device was easy to use and helped avoid wasted medication.

Reference
Steger JS, Capó-Aponte JE, Papp A, et al. Real-world efficacy, safety, and usability of a microvolume eyedrop delivery device in glaucoma: a prospective randomized crossover trial. J Cataract Refract Surg. 2025;doi: 10.1097/j.jcrs.0000000000001823. Epub ahead of print. PMID: 41185150.